Investigational — not available anywhere
This compound is not approved for any use and is not currently sold by any vendor, including research-chemical and RUO (“research use only”) sellers. Everything on this page comes from the developer’s own registered trials or from published research; there is no legitimate product to buy under this name, and any listing claiming otherwise should be treated with suspicion. See the full Obesity Pipeline for other compounds at this same stage.
NBIP-1968 is an investigational drug from Neurocrine Biosciences that activates three separate metabolic receptors, GLP-1, GIP, and glucagon, in a single molecule, the same general strategy behind retatrutide. It is designed as a once-weekly injection for obesity and entered its first human trial in August 2026, testing only single doses for safety so far. Neurocrine’s stated plan is to eventually pair it with a second experimental drug, NBIP-2118, that works on a completely different pathway, aiming to address a limitation of current weight-loss drugs: they tend to reduce muscle along with fat. It has never been approved and has never been sold anywhere.
Research snapshot
| Peptide category | GLP-1/GIP/glucagon receptor triple agonist |
| Primary research interest | Obesity, with an emphasis on preserving lean mass alongside fat loss |
| Highest available evidence | None yet — Phase 1 single-ascending-dose safety trial only, in progress |
| Human research available | Yes, but limited to an ongoing Phase 1 SAD trial with no reported results |
| Development status | Phase 1 (initiated August 7, 2026) |
| Regulatory status | Not approved anywhere. Not sold under any legitimate or grey-market channel. |
| Last reviewed | September 27, 2026 |
Technical identity
| Primary name | NBIP-1968 (also styled NBIP-‘1968 in company materials) |
| Alternative names | None identified |
| Peptide sequence | Not published |
| Amino-acid length | Not reliably established |
| Molecular formula | Not reliably established |
| Molecular weight | Not reliably established |
| CAS Registry Number | Not reliably established |
| PubChem CID | Not reliably established |
| UNII | Not reliably established |
| DrugBank ID | Not listed |
| Chemical modifications | Not disclosed; company materials describe it only as “designed with balanced glucagon receptor activity to optimize the potential metabolic benefits” |
| Peptide class | Multi-receptor (triple) incretin/glucagon agonist |
| Primary biological target | GLP-1 receptor, GIP receptor, and glucagon receptor (balanced activity across all three, per developer statements) |
| Developer or originator | Neurocrine Biosciences |
| Development status | Phase 1 |
What is NBIP-1968?
NBIP-1968 is Neurocrine Biosciences’ entry into the crowded field of “triple agonist” obesity drugs, molecules engineered to activate three separate hormone receptors, GLP-1, GIP, and glucagon, at once. The best-known drug in this class is Eli Lilly’s retatrutide, which has posted some of the largest weight-loss numbers of any obesity drug in human trials to date. Neurocrine is a company best known for neuroscience and endocrine drugs rather than metabolic disease, and NBIP-1968 represents a newer push into the obesity space.
The compound entered its first human trial, a phase 1 study testing single ascending doses for safety and tolerability, on August 7, 2026. The trial enrolls adults across a range of body mass index categories, including people with overweight and obesity, but at this stage it is purely a safety and dose-finding exercise; no efficacy data, weight loss, blood sugar change, or otherwise, exists yet, and none has been promised on a specific timeline.
What sets Neurocrine’s stated strategy apart from most other triple-agonist programs is not the receptor combination itself, several companies are chasing that same three-receptor target, but a planned second act: pairing NBIP-1968 with a separate experimental drug, NBIP-2118, a corticotropin-releasing factor type 2 (CRF2) receptor agonist, also in its own early phase 1 trial. CRF2 is part of the stress-hormone signaling system, a pathway essentially unrelated to the GLP-1/GIP/glucagon axis, and Neurocrine has stated the rationale for combining the two is to address a widely discussed limitation of current GLP-1-class obesity drugs: they tend to reduce lean muscle mass along with fat mass. Whether that combination actually preserves lean mass better than a triple agonist alone has not been tested in any completed human trial.
How does it work?
Plain-English explanation
Your body uses several different hormone signals to manage hunger, blood sugar, and energy use after a meal. Most current obesity drugs, like semaglutide, copy just one of those signals, GLP-1. NBIP-1968 is designed to copy three of them at once, GLP-1, GIP, and glucagon, in a single weekly injection, on the theory that hitting all three pathways together produces a bigger metabolic effect than hitting just one, which is the same logic behind Eli Lilly’s retatrutide.
Technical explanation
NBIP-1968 is described by its developer as a long-acting, once-weekly subcutaneous triple agonist with activity at the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Neurocrine has specifically stated the molecule was “designed with balanced glucagon receptor activity to optimize the potential metabolic benefits,” language that echoes a known engineering challenge in this drug class: glucagon receptor agonism can meaningfully add to weight loss and metabolic effect, but too much of it has historically raised tolerability concerns, which is presumably why “balanced” rather than “maximal” glucagon activity is being emphasized in company messaging. No receptor-binding potency data, pharmacokinetic parameters, or structural details have been published as of this review.
Potential benefits and research applications
Weight management via triple-receptor agonism
The entire premise of this program, and the reason it exists as a phase 1 candidate at all, is the hypothesis that combined GLP-1/GIP/glucagon agonism produces greater weight loss than single- or dual-receptor drugs, a hypothesis retatrutide’s phase 2 data has already supported for that specific molecule. No comparable data exists yet for NBIP-1968 itself. Evidence: is being investigated for (phase 1 trial ongoing, no results reported); has not been established for this specific molecule, though the mechanistic class has supporting evidence from other compounds.
Lean mass preservation via combination with NBIP-2118
Neurocrine’s stated long-term plan is a fixed-dose combination of NBIP-1968 with NBIP-2118, aimed at reducing the muscle loss commonly seen alongside fat loss on GLP-1-class drugs. NBIP-2118 works through the CRF2 receptor, part of the stress-hormone (corticotropin-releasing factor) system, a mechanism that has no established, completed human evidence for lean-mass preservation in this context as of this review. Evidence: is being investigated for, a theoretical rationale stated by the developer; no combination trial has been completed or, as of this review, started; has not been established in any human data.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate. NBIP-1968 has never been sold anywhere, legitimately or otherwise. It exists only inside a single, currently enrolling phase 1 trial, and no dose amounts have been disclosed publicly.
The only phase 1 first-in-human safety trial is testing single ascending dose cohorts by subcutaneous injection; specific milligram amounts have not been published, though the intended eventual product is a once-weekly injection. There is nothing else to reconcile here: exactly one dose-related fact is public, that the trial is testing single ascending doses of a once-weekly-intended subcutaneous drug, and even that comes from a company press release, not a completed disclosure of actual dose amounts. This is the earliest-stage compound covered anywhere on this site, and this section reflects that honestly rather than manufacturing detail that does not exist yet.
| Reported use or research objective | Route reported | Amount reported | Frequency reported | Reported duration | Evidence or source category |
|---|---|---|---|---|---|
| Phase 1 first-in-human safety trial | Subcutaneous | Not disclosed — single ascending dose cohorts, specific mg amounts not published | Single dose per cohort (SAD design); intended eventual product is once weekly | Trial ongoing, initiated August 2026 | Registered but unpublished human trial |
| Practitioner or community protocols | — | — | — | — | Not consistently reported — no established or reliably sourced dosing information exists |
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| Phase 1 first-in-human safety trial | Subcutaneous | Not disclosed; single ascending dose cohorts, specific mg amounts not published | Single dose per cohort (SAD design); intended eventual product is once weekly | Trial ongoing, initiated August 2026 |
| Community, forum, or vendor protocol | Not applicable | Not applicable; no established or reliably sourced dosing information exists | Not applicable | Not applicable |
No established or reliably sourced consumer dosing information was identified. NBIP-1968 has never been sold anywhere, legitimately or otherwise; it exists only inside one active, sponsor-controlled phase 1 trial, and no dose amounts from that trial have been publicly disclosed.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Side effects, risks, and limitations
No human safety data has been reported yet; the phase 1 trial evaluating this is still ongoing as of this review, and companies typically do not disclose adverse-event data from an active single-ascending-dose study until it completes. Based on the drug class, GLP-1/GIP/glucagon triple agonists, the developer’s own framing anticipates the standard tolerability concerns associated with glucagon receptor agonism, principally nausea and other gastrointestinal effects, which is presumably why “balanced” rather than maximal glucagon activity was built into the design; whether that design choice actually improves tolerability compared to other triple agonists like retatrutide has not been tested. Because NBIP-1968 has never been sold outside this one sponsor-controlled trial, there is no purity, contamination, or counterfeit-product concern to report.
Regulatory and developmental status
NBIP-1968 is not approved anywhere and has no regulatory filing of any kind. It is in phase 1 (single ascending dose) human testing, initiated August 7, 2026, by Neurocrine Biosciences. No phase 2 timeline, regulatory strategy, or partnering announcement has been made public as of this review.
Frequently asked questions
What is NBIP-1968?
An investigational drug from Neurocrine Biosciences that activates three metabolic receptors, GLP-1, GIP, and glucagon, at once, aimed at treating obesity. It is the same general drug class as Eli Lilly’s retatrutide.
How does NBIP-1968 work?
It is designed to mimic three separate hormone signals your body uses to regulate appetite, blood sugar, and energy use, delivered as a single once-weekly injection once dosing moves past the current single-dose safety testing.
What dosage has been studied?
None has been publicly disclosed. The only trial running is a phase 1 single-ascending-dose safety study, and specific dose amounts have not been released.
What dosage commonly circulates online?
None. NBIP-1968 has never been available for purchase anywhere; it exists only inside one active clinical trial.
Has NBIP-1968 been studied in humans?
Yes, but only in an ongoing phase 1 safety trial that began in August 2026. No efficacy or full safety data has been reported.
Is NBIP-1968 approved?
No, and it is not close: phase 1 is the very first stage of human testing.
How does NBIP-1968 compare to retatrutide?
Both are GLP-1/GIP/glucagon triple agonists, but retatrutide is years ahead in development with substantial published phase 2 human data, while NBIP-1968 has none yet. Neurocrine’s differentiation strategy centers less on the triple-agonist mechanism itself and more on a planned future combination with NBIP-2118 to address lean-mass loss.
What remains unknown?
Essentially everything beyond the mechanism and the fact that human testing has begun: safety, tolerability, effective dose, weight-loss magnitude, and whether the planned NBIP-2118 combination will ever be tested, let alone work as intended.
Bottom line
NBIP-1968 is Neurocrine Biosciences’ newly launched entry into the triple-agonist obesity race, a mechanistic class already led by Eli Lilly’s retatrutide, and as of this review it has produced zero human data beyond the fact that a single-ascending-dose safety trial started in August 2026. Its most interesting feature is not the molecule itself but Neurocrine’s stated plan to eventually pair it with NBIP-2118, a completely different, stress-hormone-pathway drug, to try to solve the lean-mass-loss problem that shadows the entire GLP-1 drug class. That combination has not been tested yet, and will not have even early data until at least 2027 based on NBIP-2118’s own disclosed timeline. This is about as early-stage as an obesity-pipeline entry gets, and the page reflects that: no dosage, no efficacy, no technical identifiers, just a real trial that just started.